Payment overview · 2025
General Payments
$424.50
25 reported records · 12 companies
Healthcare provider profile · identity verified
Amanda Butcher
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SAGINAW, MI · NPI 1497360580
Verified facts
What the public records show
CMS Open Payments records show Amanda Butcher received $424.50 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $120.94 | 28.5% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.91 | 11.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.48 | 11.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.57 | 10.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.24 | 8.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.87 | 7.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.39 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.97 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.18 | 3.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.93 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.60 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.42 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.50 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.16 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 152 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 53 |
| Sertraline Hcl | Sertraline Hcl | 342 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 43 |
| Furosemide | Furosemide | 275 | 48 |
| Lisinopril | Lisinopril | 262 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 228 | 30 |
| Buspirone Hcl | Buspirone Hcl | 224 | 36 |
| Memantine Hcl | Memantine Hcl | 221 | 27 |
| Omeprazole | Omeprazole | 213 | 32 |
| Donepezil Hcl | Donepezil Hcl | 198 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 31 |
| Metformin Hcl | Metformin Hcl | 192 | 27 |
| Trazodone Hcl | Trazodone Hcl | 188 | 29 |
| Gabapentin | Gabapentin | 186 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 23 |
| Potassium Chloride | Potassium Chloride | 173 | 28 |
| Eliquis | Apixaban | 152 | 22 |
| Mirtazapine | Mirtazapine | 152 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 128 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 17 |
| Divalproex Sodium | Divalproex Sodium | 110 | 13 |
| Simvastatin | Simvastatin | 106 | 15 |
| Famotidine | Famotidine | 105 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 19 |
| Cephalexin | Cephalexin | 92 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | suppressed |
| Jardiance | Empagliflozin | 80 | suppressed |
| Finasteride | Finasteride | 76 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 74 | 14 |
| Aripiprazole | Aripiprazole | 69 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 68 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Spironolactone | Spironolactone | 62 | suppressed |
| Lorazepam | Lorazepam | 59 | 25 |
| Prednisone | Prednisone | 57 | 24 |
| Carvedilol | Carvedilol | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Nystatin | Nystatin | 53 | 25 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 14 |
| Midodrine Hcl | Midodrine Hcl | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Nyamyc | Nystatin | 37 | 19 |
| Baclofen | Baclofen | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Losartan Potassium | Losartan Potassium | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Risperidone | Risperidone | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Digoxin | Digoxin | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Naproxen | Naproxen | 18 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Nystop | Nystatin | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Methimazole | Methimazole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Betaseron | Interferon Beta-1b | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.50 · 25 records | PFIZER INC. | AIRSUPRA, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, ENFLONSIA, FANAPT, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, TRUMENBA, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error